The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

HOUSTON, TEXAS / ACCESS Newswire / July 1, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an ...

(HealthDay News) — For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability Assessment (MIDAS) scores, according ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

Weight loss isn’t just cosmetic; it prevents chronic disease, saves money and improves mental and physical well-being.

Two of the distinguished in the latest edition of the Fronteras del Conocimiento FBBVA, endocrinologist Daniel J. Drucker and ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...